

10849,088

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal201txs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded  
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification  
data  
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles  
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India  
NEWS 8 JAN 29 PHAR reloaded with new search and display fields  
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000  
in  
multiple databases  
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 13 FEB 26 MEDLINE reloaded with enhancements  
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000  
to 300,000 in multiple databases  
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 19 MAR 16 CASREACT coverage extended  
NEWS 20 MAR 20 MARPAT now updated daily  
NEWS 21 MAR 22 LWPI reloaded  
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN  
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field  
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records  
NEWS 26 APR 30 CA/CAPLUS enhanced with 1870-1889 U.S. patent records  
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN  
NEWS 28 MAY 01 New CAS web site launched  
  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

11/849,088

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:02:14 ON 01 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:02:29 ON 01 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 APR 2007 HIGHEST RN 933825-30-0

DICTIONARY FILE UPDATES: 30 APR 2007 HIGHEST RN 933825-30-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10849088.str

11/849,088



chain nodes :

20

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

9-20 10-17 13-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12  
12-13 13-14 15-16 15-19 16-17 17-18 18-19

exact/norm bonds :

6-9 7-8 8-9 9-20 12-13

exact bonds :

5-7 10-11 10-14 10-17 11-12 13-14 13-20 15-16 15-19 16-17 17-18  
18-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 10 : 15 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom  
18:Atom 19:Atom 20:CLASS

11/849,088

L1           STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 15:02:50 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -           16 TO ITERATE

100.0% PROCESSED           16 ITERATIONS                           2 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*  
                          BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:       80 TO       560  
PROJECTED ANSWERS:           2 TO       124

L2           2 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 15:02:55 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -           264 TO ITERATE

100.0% PROCESSED           264 ITERATIONS                       58 ANSWERS  
SEARCH TIME: 00.00.01

L3           58 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 15:03:05 ON 01 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 May 2007 VOL 146 ISS 19  
FILE LAST UPDATED: 30 Apr 2007 (20070430/ED)

11/849,088

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 1 L3

=> d l4 ibib hitstr abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:1011963 CAPLUS  
DOCUMENT NUMBER: 142:6526  
TITLE: Preparation of indazolecarboxamides as factor VIIa  
and/or factor Xa inhibitors  
INVENTOR(S): Nazare, Marc; Wehner, Volkmar; Laux, Volker;  
Urmann,  
Matthias; Bauer, Armin; Matter, Hans  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: Eur. Pat. Appl., 103 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1479675	A1	20041124	EP 2003-11303	20030519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004238499	A1	20041125	AU 2004-238499	20040505
CA 2528220	A1	20041125	CA 2004-2528220	20040505
WO 2004101556	A1	20041125	WO 2004-EP4753	20040505
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1628972	A1	20060301	EP 2004-731155	20040505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004010430	A	20060606	BR 2004-10430	20040505
JP 2006528942	T	20061228	JP 2006-529742	20040505
US 2004235824	A1	20041125	US 2004-849088 ✓	20040519
PRIORITY APPLN. INFO.:			EP 2003-11303	A 20030519

11/849,088

US 2003-507171P P 20030930

WO 2004-EP4753 W 20040505

OTHER SOURCE(S): CASREACT 142:6526; MARPAT 142:6526

IT 797803-86-2P 797803-87-3P 797803-88-4P  
797803-89-5P 797803-90-8P 797803-91-9P  
797803-92-0P 797803-93-1P 797803-94-2P  
797803-95-3P 797803-96-4P 797803-97-5P  
797803-98-6P 797803-99-7P 797804-00-3P  
797804-01-4P 797804-02-5P 797804-03-6P  
797804-04-7P 797804-05-8P 797804-06-9P  
797804-07-0P 797804-08-1P 797804-09-2P  
797804-10-5P 797804-11-6P 797804-12-7P  
797804-13-8P 797804-14-9P 797804-15-0P  
797804-16-1P 797804-18-3P 797804-19-4P  
797804-21-8P 797804-23-0P 797804-25-2P  
797804-27-4P 797804-28-5P 797804-29-6P  
797804-30-9P 797804-31-0P 797804-34-3P  
797804-35-4P 797804-36-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(claimed compound; preparation of indazolecarboxamides as factor  
VIIa and/or  
factor Xa inhibitors)

RN 797803-86-2 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,  
methyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-87-3 CAPLUS

CN 1H-Indazole-6-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,  
methyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-88-4 CAPLUS

CN 1H-Indazole-7-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,  
methyl ester (9CI) (CA INDEX NAME)



11/849,088




RN 797803-89-5 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazoly]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-  
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-90-8 CAPLUS

CN 1H-Indazole-7-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-  
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-91-9 CAPLUS

CN 1H-Indazole-6-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-  
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-92-0 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

11/849,088




RN 797803-93-1 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,  
1-[(ethoxycarbonyl)oxy]ethyl ester (9CI) (CA INDEX NAME)

11/849,088




RN 797803-94-2 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

4-cyano-N-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

11/849,088




RN 797803-95-3 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

11/849,088



RN 797803-96-4 CAPLUS

CN 1H-Indazole-3-carboxamide, 5-(1-azetidinyldicarbonyl)-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-  
(9CI)


(CA INDEX NAME)



CC(C)N1CCN(CC1)NC(=O)c2nc3ccccc3n2Cn4cc5cc(Cl)cc5o4

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-N5-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)

11/849,088




RN 797803-98-6 CAPLUS


CN 1H-Indazole-3,5-dicarboxamide,

N5-[2-(aminosulfonyl)ethyl]-1-[[5-(5-chloro-  
2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-  
(9CI) (CA INDEX NAME)

11/849,088




RN 797803-99-7 CAPLUS  
CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidiny]-N5-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 797804-00-3 CAPLUS

11/849,088


CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidiny]-N5-[(trimethylsilyl)methyl]- (9CI) (CA INDEX NAME)



RN 797804-01-4 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5,N5-bis(2-hydroxyethyl)-N3-[1-(1-methylethyl)-4-piperidiny]- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-02-5 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-N5-(2-hydroxyethyl)-N5-methyl-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-03-6 CAPLUS

CN Glycine, N-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)


11/849,088



RN 797804-04-7 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-(2,2-difluoroethyl)-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

11/849,088



RN 797804-05-8 CAPLUS


CN 1H-Indazole-3,5-dicarboxamide,

N5-(2-amino-2-oxoethyl)-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidinyl]-  
(9CI)

(CA INDEX NAME)




11/849,088



RN 797804-06-9 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-(2-hydroxyethyl)-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-07-0 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-[1-(1-methylethyl)-4-piperidiny]l]-N3-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-08-1 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-N5-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-09-2 CAPLUS

CN Glycine, N-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-  
(9CI) (CA INDEX NAME)

11/849,088




RN 797804-10-5 CAPLUS

CN 2-Azetidinecarboxylic acid, 1-[[[1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 797804-11-6 CAPLUS

11/849,088


CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N3-[1-(1-methylethyl)-4-piperidiny]-N5-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 797804-12-7 CAPLUS

CN Glycine, N-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-1H-indazol-5-yl]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)


11/849,088



RN 797804-13-8 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-, 2-hydroxyethyl ester (9CI) (CA INDEX NAME)

11/849,088



RN 797804-14-9 CAPLUS


CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[1-(1-methylethyl)-4-piperidyl]-5-[(tetrahydro-1,4-oxazin-4(5H)-yl)carbonyl]- (9CI) (CA INDEX NAME)



11/849,088




RN 797804-15-0 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

5-[(3-hydroxy-1-azetidinyl)carbonyl]-N-[1-(1-methylethyl)-4-piperidinyl]-  
(9CI) (CA INDEX NAME)

11/849,088




RN 797804-16-1 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-methoxy-N3-[1-(1-methylethyl)-4-piperidinyl]-  
(9CI)

(CA INDEX NAME)

11/849,088





RN 797804-18-3 CAPLUS



CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[4-(1-pyrrolidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 797804-19-4 CAPLUS  
 CN 1H-Indazole-3-carboxamide,  
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
 N-[4-(4-morpholinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 797804-21-8 CAPLUS  
 CN Piperidine,  
 1-[[1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-1H-indazol-3-yl]carbonyl]-4-(2-oxo-1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

11/849,088




RN 797804-23-0 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




/  
Cl

RN 797804-25-2 CAPLUS

CN 1H-Indazole-3-carboxamide,

1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-


N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 797804-27-4 CAPLUS  
 CN 1H-Indazole-3-carboxamide,  
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
 N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]- (9CI)  
 (CA INDEX NAME)





PAGE 1-A




PAGE 2-A



RN 797804-28-5 CAPLUS  
 CN 1H-Indazole-3-carboxamide,  
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
 N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)





RN 797804-29-6 CAPLUS  
 CN 1H-Indazole-3-carboxamide,  
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
 N-[4-(1H-imidazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




/  
Cl

RN 797804-30-9 CAPLUS  
 CN 1H-Indazole-3-carboxamide,  
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
 N-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 797804-31-0 CAPLUS  
CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 797804-34-3 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl)methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,  
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (9CI) (CA INDEX NAME)


11/849,088



RN 797804-35-4 CAPLUS

CN 1H-Indazole-3,5-dicarboxamide, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N5-cyano-N3-[1-(1-methylethyl)-4-piperidinyl]- (9CI)  
(CA INDEX NAME)


11/849,088



RN 797804-36-5 CAPLUS

CN 3-Azetidinecarboxylic acid, 1-[[1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-1H-indazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)



IT 797804-39-8P 797804-40-1P 797804-42-3P  
 797804-43-4P 797804-44-5P 797804-46-7P  
 797804-47-8P 797804-49-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of indazolecarboxamides as factor VIIa and/or factor Xa  
 inhibitors)

RN 797804-39-8 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,  
 methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 797803-86-2

CMF C26 H28 Cl N5 O4 S




11/849,088



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 797804-40-1 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,  
hydrochloride (9CI) (CA INDEX NAME)

11/849,088




●x HCl

RN 797804-42-3 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-,  
1-[(ethoxycarbonyl)oxy]ethyl ester, hydrochloride (9CI) (CA INDEX  
NAME)




●x HCl

RN 797804-43-4 CAPLUS  
 CN 1H-Indazole-3-carboxamide,  
 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
 4-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)-N-[1-(1-methylethyl)-4-  
 piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-95-3  
 CMF C26 H26 Cl N7 O4 S


11/849,088



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797804-44-5 CAPLUS


CN 1H-Indazole-3-carboxamide, 5-(1-azetidinyldicarbonyl)-1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-N-[1-(1-methylethyl)-4-piperidinyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-96-4

CMF C28 H31 Cl N6 O3 S


11/849,088



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797804-46-7 CAPLUS

CN 1H-Indazole-3-carboxamide,


1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-

N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 797804-23-0


CMF C26 H20 Cl N5 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 797804-47-8 CAPLUS

CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-[[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-,

11/849,088


methyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 797804-31-0

CMF C28 H22 Cl N5 O6 S

PAGE 1-A



PAGE 2-A




CM 2

CRN 76-05-1

CMF C2 H F3 O2

11/849,088



RN 797804-49-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazoly]methyl]-3-[[[1-(1-methylethyl)-4-piperidinyl]amino]carbonyl]-,  
(5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl ester, hydrochloride (9CI)

(CA

INDEX NAME)

PAGE 1-A



PAGE 2-A

●x HCl

IT 797804-62-7

RL: RCT (Reactant); RACT (Reactant or reagent)



11/849,088

(preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors)

RN 797804-62-7 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-

isoxazolyl]methyl]-3-[[[1-(1-methylethyl)-4-piperidiny]amino]carbonyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 797803-89-5


CMF C25 H26 Cl N5 O4 S



CM 2

CRN 64-19-7

CMF C2 H4 O2




IT 797804-51-4P 797804-57-0P 797804-58-1P  
797804-59-2P

11/849,088

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT  
(Reactant or reagent)  
(preparation of indazolecarboxamides as factor VIIa and/or factor Xa inhibitors)


RN 797804-51-4 CAPLUS

CN 1H-Indazole-3,5-dicarboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-, 5-methyl ester (9CI) (CA INDEX NAME)



RN 797804-57-0 CAPLUS


CN 1H-Indazole-4-carbonitrile, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-3-formyl- (9CI) (CA INDEX NAME)




RN 797804-58-1 CAPLUS

CN 1H-Indazole-3-carboxylic acid, 1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-4-cyano- (9CI) (CA INDEX NAME)


11/849,088




RN 797804-59-2 CAPLUS  
CN 1H-Indazole-3-carboxamide,  
1-[[5-(5-chloro-2-thienyl)-3-isoxazolyl]methyl]-  
4-[(hydroxyamino)iminomethyl]-N-[1-(1-methylethyl)-4-piperidinyl]-  
(9CI)  
(CA INDEX NAME)



GI



I



II

AB Title compds. [I, II; R = (substituted) mono- or bicyclic aryl, heterocyclyl; D = atoms to form a (substituted) 4-8 membered (heterocyclic) (aromatic) ring; R1 = H, (substituted) alkyl, aminocarbonylalkyl, alkoxy carbonylalkyl, aryl, heterocyclyl, etc.; R2 = bond, alkylene; V = (substituted) heterocyclyl, aryl; G = bond, (CH2)mNR10SO2(CH2)n, (CH2)mNR10SO2(CH2)n, (CH2)mCH(OH)(CH2)n, (CH2)m, (CH2)mO(CH2)n, (CH2)mS(CH2)n, etc.; m, n = 0-6; R10 = H, alkyl, hydroxyalkyl, alkoxyalkyl, perfluoroalkyl, with provisos], were prepared

Thus, 1-[5-(5-chlorothien-2-yl)isoxazol-3-ylmethyl]-5-(cyanamide-1-carbonyl)-1H-indazole-3-carboxylic acid

(1-isopropylpiperidin-4-yl)amide

(preparation outlined) inhibited factor Xa with Ki = 5 nM.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.74	178.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-0.78

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 15:03:30 ON 01 MAY 2007